Overcoming Downstream Challenges In Next-Generation Antibody Development

Next-generation antibodies—such as multi-specifics and antibody fragments—offer incredible potential to treat previously incurable patient conditions. However, transforming these complex biologics into therapeutics that meet GMP compliance and are ready for large-scale manufacturing is a major hurdle. Successful development requires a strategic shift: adopting a "design with the end in mind" mindset, which integrates commercial readiness into process development from the earliest stages.

In this webinar, industry experts share practical strategies to overcome the most pressing downstream purification and process challenges associated with these novel modalities. Learn how to streamline purification workflows, dramatically accelerate development timelines, and establish robust processes that are scalable for both clinical trials and commercial production. Understand the critical steps required to navigate the complexities of multi-specific and fragment purification and enable the successful translation of promising molecules into life-changing therapies.

Access the presentation below to learn more.